IL1B and neoplasm: IL-1β is abundant in the TME, where this cytokine can promote tumor growth and presents anti-tumor activities; thus, alteration of TME from pro-invasive inflammation towards anti-tumor cell immunity against an overwhelming immunosuppressive situation is a strategy for treating cancer (35).